Targets › KIF18A
2 programs from 2 companies in 2 trials: 2 Phase 1; Oncology; next expected readout Apr 2027.
Microtubule-depolymerizing kinesin which plays a role in chromosome congression by reducing the amplitude of preanaphase oscillations and slowing poleward movement during anaphase, thus suppressing chromosome movements. May stabilize the CENPE-BUB1B complex at the kinetochores during early mitosis and maintains CENPE levels at kinetochores during chromosome congression. (UniProt, Q8NI77)
Open in Phaseline: the race on KIF18A, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Accent Therapeutics | ATX-295 KIF18A inhibitor | KIF18A | Phase 1 | Advanced Solid Tumors | Apr 2027 |
| Suzhou Genhouse Bio Co., Ltd. | GH2616 KIF18A inhibitor | KIF18A | Phase 1 | Advanced Solid Tumor Cancer | Dec 2028 |
Advanced Solid Tumors (1) Advanced Solid Tumor Cancer (1)
mixed (1), small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.